IN THE NEWS

« Previous Release | Next Release »

BOTHELL, Wash., -- Cardiac Science Corporation, a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, entered into an exclusive agreement with OMRON Healthcare distribute Omron's vital signs and spot check monitors under the Cardiac Science brand in the United States and Canada. OMRON Healthcare is a subsidiary of OMRON Corporation, the $7-billion global leader in the sensing and control market and the global leader in blood pressure monitoring with sales of more than 100 million blood pressure units worldwide.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO )

"This deal leverages our industry-leading distribution capabilities. OMRON is an outstanding company with an excellent reputation for quality," said Dave Marver, Cardiac Science's president and chief executive officer. "They are an ideal partner to help us enter the North American vital signs market."

"When we looked to expand our U.S. based sales into the diagnostic market for healthcare professionals," said Bob Kondraske, chief operating officer for OMRON Healthcare, Inc., "we needed a partner with deep industry knowledge and solid distribution. Cardiac Science is a leader in ECG, Holter, cardiac stress, and automated external defibrillation sales into the physician office. In addition, they have a strong direct sales force in the hospital market. They've demonstrated their commitment and skill selling into both marketplaces - which is exactly what we needed."

Vital signs monitors sold under the exclusive agreement are available for sale next Monday under the Cardiac Science name, while clearly featuring the accuracy of the OMRON technology. "This allows customers to recognize the strengths of both brands, and know they're purchasing from a partnership comprising two world leaders," Kondraske added.

About Cardiac Science

Cardiac Science, a wholly owned subsidiary of Opto Circuits (India) Ltd., develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, PC-based diagnostic workstations, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick^®, HeartCentrix^®, Powerheart^®, and Quinton^® brands, is headquartered in Bothell, Washington. With customers in almost 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

Forward-Looking Statements

This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's future AED sales in Japan, expected shipments of backordered products in the fourth quarter of 2010, and expectations regarding the closing of the transaction with Opto Circuits. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results and performance may vary significantly from those expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks include those more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2009, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.

For updates and information on worldwide defibrillation and cardiac monitoring, find us on Facebook at http://facebook.com/cardiacscience, the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, and YouTube at http://budurl.com/CSonYT

For more information, contact (media) info@cardiacscience.com | (investors) ir@optoindia.com | +91.80.2852.8088